These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35420123)

  • 21. Early mortality during rifampicin-resistant TB treatment.
    Mohr-Holland E; Daniels J; Reuter A; Rodriguez CA; Mitnick C; Kock Y; Cox V; Furin J; Cox H
    Int J Tuberc Lung Dis; 2022 Feb; 26(2):150-157. PubMed ID: 35086627
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and safety of bedaquiline under conditional access program for treatment of drug-resistant tuberculosis in India: An interim analysis.
    Salhotra VS; Sachdeva KS; Kshirsagar N; Parmar M; Ramachandran R; Padmapriyadarsini C; Patel Y; Mehandru L; Jaju J; Ponnuraja C; Gupta M; Kalaiselvan V; Shamim A; Khaparde S; Swaminathan S;
    Indian J Tuberc; 2020 Jan; 67(1):29-37. PubMed ID: 32192613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Profile of Multidrug Tuberculosis Regimen and Treatment Outcomes in Pulmonary MDR-TB Patients at the Tertiary Referral Hospital Dr. Soetomo, East Java, Indonesia: A Seven-Year Retrospective Study on Bedaquiline.
    Setyawan MF; Mertaniasih NM; Soedarsono S
    Acta Med Indones; 2023 Oct; 55(4):430-439. PubMed ID: 38213049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Switching to bedaquiline for treatment of rifampicin-resistant tuberculosis in South Africa: A retrospective cohort analysis.
    Bouton TC; de Vos M; Ragan EJ; White LF; Van Zyl L; Theron D; Horsburgh CR; Warren RM; Jacobson KR
    PLoS One; 2019; 14(10):e0223308. PubMed ID: 31622366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs.
    Clemens DL; Lee BY; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA
    PLoS One; 2019; 14(5):e0215607. PubMed ID: 31075149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and Effectiveness of an All-Oral, Bedaquiline-Based, Shorter Treatment Regimen for Rifampicin-Resistant Tuberculosis in High Human Immunodeficiency Virus (HIV) Burden Rural South Africa: A Retrospective Cohort Analysis.
    Tack I; Dumicho A; Ohler L; Shigayeva A; Bulti AB; White K; Mbatha M; Furin J; Isaakidis P
    Clin Infect Dis; 2021 Nov; 73(9):e3563-e3571. PubMed ID: 33372989
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and effectiveness of all-oral and injectable-containing, bedaquiline-based long treatment regimen for pre-XDR tuberculosis in Vietnam.
    Nguyen TMP; Nguyen BH; Hoang TTT; Nguyen HA; Vu DH; Nguyen MH; Nguyen BN; Decroo T; Nguyen VN
    Front Pharmacol; 2022; 13():1023704. PubMed ID: 36313324
    [No Abstract]   [Full Text] [Related]  

  • 28. One Step Forward: Successful End-of-Treatment Outcomes of Patients With Drug-Resistant Tuberculosis Who Received Concomitant Bedaquiline and Delamanid in Mumbai, India.
    Das M; Dalal A; Laxmeshwar C; Ravi S; Mamnoon F; Meneguim AC; Paryani R; Mathur T; Singh P; Mansoor H; Kalon S; Hossain FN; Lachenal N; Coutisson S; Ferlazzo G; Isaakidis P
    Clin Infect Dis; 2021 Nov; 73(9):e3496-e3504. PubMed ID: 33079176
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of the side effect of QTc interval prolongation in the bedaquiline regimen in drug resistant tuberculosis patients.
    Ardhianto D; Suharjono ; Soedarsono ; Fatmawati U
    J Basic Clin Physiol Pharmacol; 2021 Jun; 32(4):421-427. PubMed ID: 34214323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduced Susceptibility of Mycobacterium tuberculosis to Bedaquiline During Antituberculosis Treatment and Its Correlation With Clinical Outcomes in China.
    Liu Y; Gao M; Du J; Wang L; Gao J; Shu W; Wang Y; Xue Z; Li L; Pang Y
    Clin Infect Dis; 2021 Nov; 73(9):e3391-e3397. PubMed ID: 32667984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Injectables' key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes.
    Decroo T; Maug AKJ; Hossain MA; Uwizeye C; Gumusboga M; Demeulenaere T; Ortuño-Gutiérrez N; de Jong BC; Van Deun A
    PLoS One; 2020; 15(8):e0238016. PubMed ID: 32866193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment outcomes in patients with drug-resistant TB-HIV co-infection treated with bedaquiline and linezolid.
    Padayatchi N; Bionghi N; Osman F; Naidu N; Ndjeka N; Master I; Brust JCM; Naidoo K; Ramjee A; O Donnell M
    Int J Tuberc Lung Dis; 2020 Oct; 24(10):1024-1031. PubMed ID: 33126934
    [No Abstract]   [Full Text] [Related]  

  • 33. Fluoroquinolones for the treatment of pulmonary tuberculosis.
    Moadebi S; Harder CK; Fitzgerald MJ; Elwood KR; Marra F
    Drugs; 2007; 67(14):2077-99. PubMed ID: 17883288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis.
    Ndjeka N; Conradie F; Schnippel K; Hughes J; Bantubani N; Ferreira H; Maartens G; Mametja D; Meintjes G; Padanilam X; Variava E; Pym A; Pillay Y
    Int J Tuberc Lung Dis; 2015 Aug; 19(8):979-85. PubMed ID: 26162365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is 6 months of bedaquiline enough? Results from the compassionate use of bedaquiline in Armenia and Georgia.
    Hewison C; Bastard M; Khachatryan N; Kotrikadze T; Hayrapetyan A; Avaliani Z; Kiria N; Yegiazaryan L; Chumburidze N; Kirakosyan O; Atshemyan H; Qayyum S; Lachenal N; Varaine F; Huerga H
    Int J Tuberc Lung Dis; 2018 Jul; 22(7):766-772. PubMed ID: 29914602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
    Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen.
    Ndjeka N; Schnippel K; Master I; Meintjes G; Maartens G; Romero R; Padanilam X; Enwerem M; Chotoo S; Singh N; Hughes J; Variava E; Ferreira H; Te Riele J; Ismail N; Mohr E; Bantubani N; Conradie F
    Eur Respir J; 2018 Dec; 52(6):. PubMed ID: 30361246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis.
    Pai H; Ndjeka N; Mbuagbaw L; Kaniga K; Birmingham E; Mao G; Alquier L; Davis K; Bodard A; Williams A; Van Tongel M; Thoret-Bauchet F; Omar SV; Bakare N
    BMC Infect Dis; 2022 Nov; 22(1):870. PubMed ID: 36414938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis.
    Park S; Jo KW; Lee SD; Kim WS; Shim TS
    Respir Med; 2017 Oct; 131():43-48. PubMed ID: 28947041
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness and safety of bedaquiline-based, modified all-oral 9-11-month treatment regimen for rifampicin-resistant tuberculosis in Vietnam.
    Nguyen TMP; Le THM; Merle CSC; Pedrazzoli D; Nguyen NL; Decroo T; Nguyen BH; Hoang TTT; Nguyen VN
    Int J Infect Dis; 2023 Jan; 126():148-154. PubMed ID: 36372364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.